Key insights
- Brightspring Health Services reported strong Q1 2026 earnings, beating EPS forecasts by a wide margin. Revenue also showed substantial growth. The stock price jumped 11.49% in premarket trading, reflecting positive investor sentiment. While positive for the company, the limited market cap suggests a contained influence on broader US equities.
Brightspring Health Services Inc. reported its first-quarter 2026 earnings, surpassing expectations with an EPS of $0.39, significantly above the forecasted $0.16. The company’s revenue reached $3.61 billion. Following the earnings announcement, the stock saw a notable premarket increase of 11.49%, reaching $48.50. This positive market reaction reflects investor confidence in the company’s performance and strategic positioning in the healthcare sector.
Brightspring Health Services has demonstrated robust performance in the first quarter of 2026. The company is capitalizing on major healthcare trends, such as the aging population and increased demand for home and community health services. Its strategic focus on specialty pharmacy and infusion markets has positioned it well for continued growth. The company reported strong census growth in its home healthcare segment and successful integration of acquired assets, contributing significantly to its revenue. InvestingPro data shows revenue growth of 28% over the last twelve months, while the platform’s Financial Health Score rates the company as "GREAT" with particularly strong marks for price momentum. An InvestingPro tip highlights that Brightspring is a prominent player in the Healthcare Providers & Services industry, with analysts predicting continued profitability this year.
Brightspring Health Services reported an EPS of $0.39, significantly exceeding the forecasted $0.16, resulting in a 143.75% earnings surprise. This marks a substantial improvement from previous quarters, indicating strong operational performance and effective cost management.
Following the earnings announcement, Brightspring’s stock price increased by 11.49% in premarket trading, reaching $48.50. This surge reflects positive investor sentiment and confidence in the company’s strategic direction. The stock’s performance is notable against its 52-week range, nearing its high of $54.29. The company’s market capitalization now stands at $9.83 billion, with the stock delivering an impressive 168% return over the past year. According to InvestingPro analysis, the stock is currently trading above its Fair Value, placing it among the most overvalued stocks in the healthcare sector—a consideration for investors evaluating entry points despite the strong momentum.
Brightspring Health Services has projected strong future performance with EPS forecasts for subsequent quarters in 2026 ranging from $0.40 to $0.51. The company anticipates continued revenue growth, with projections reaching approximately $14.85 billion for FY2026 and $16.78 billion for FY2027. For investors seeking deeper insights, Brightspring is one of the 1,400+ US equities covered by comprehensive Pro Research Reports, which transform complex Wall Street data into clear, actionable intelligence through intuitive visuals and expert analysis.
Executives highlighted the company’s strategic positioning in the healthcare market, emphasizing its focus on specialty pharmacy and infusion markets. They noted the company’s competitive advantage in exclusive and ultra-narrow LDD distribution, as well as its ongoing investments in automation to drive profitable growth.
During the earnings call, analysts inquired about Brightspring’s strategies for geographic expansion and its approach to managing the impacts of the Inflation Reduction Act. Executives provided insights into the company’s focus on expanding its infusion market coverage and leveraging automation to enhance operational efficiency.
Ann Hynes, Analyst, Mizuho3: Hello, and thank you for standing by. Welcome to BrightSpring Health Services, Inc. first quarter 2026 earnings conference call. I would now like to hand the conference over to David Deuchler. Please go ahead.
David Deuchler, Investor Relations, BrightSpring Health Services: Good morning. Thank you for participating in today’s conference call. My name is David Deuchler with Investor Relations at BrightSpring. I’m joined on today’s call by Jon Rousseau, Chief Executive Officer, and Jennifer Phipps, Chief Financial Officer. Earlier today, BrightSpring released financial results for the quarter ended March 31st, 2026. A copy of the press release and presentation is available on the company’s investor relations website. Please note that today’s discussion will include certain forward-looking statements that reflect our current assumptions and expectations, including those related to our future financial performance and industry market conditions. Such forward-looking statements are not guarantees of future performance. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our expectations.
We encourage you to review the information in today’s press release and presentation, as well as our quarterly report on Form 10-Q that will be filed with the SEC, including specific risk factors and uncertainties discussed in our Form 10-K and Form 10-Q. Such factors may be updated from time to time in our periodic filings with the SEC, and we do not undertake any duty to update any forward-looking statements except as required by law. During the call, we will use non-GAAP financial measures when talking about the company’s financial performance and financial condition. You can find additional information on these non-GAAP measures and reconciliations of our non-GAAP financial measures to the most directly comparable GAAP financial measures to the extent available without unreasonable effort in today’s earnings press release and presentation, which again, are available on our investor relations website.
This webcast is being recorded and will be available for replay on our investor relations website. With that, I will now turn the call over to Jon Rousseau, Chief Executive Officer.
Ann Hynes, Analyst, Mizuho0: Good morning, everyone, and thank you for joining BrightSpring’s first quarter 2026 earnings call. I’d like to start by thanking everyone at BrightSpring who drives our mission forward and makes a lasting impact every day. We’re grateful for their hard work and commitment, enabling us to deliver high quality and timely care to patients. Before we speak to first quarter performance, a few key messages and takeaways from our Investor Day in March and why we are optimistic about the company’s prospects in the years ahead. BrightSpring is a national leader in home and community health services, serving complex patients in the healthcare system. We deliver high-quality services at significant scale with a disciplined operating model that focuses on patient and provider outcomes. Throughout our service lines, that focus on quality care underpins commercial efforts supporting sustainable growth.
Our organizational culture of continuous improvement and best practice sharing will continue to enable operations that expand the impact we’re making in providing comparatively lower cost services for complex patients across the country. In pharmacy solutions, the growth outlook is healthy, with the specialty and infusion businesses continuing to deliver impressive script growth and patient satisfaction scores. We continue to see strong volume performance from both brand LDDs and generics, and we added 4 exclusive and ultra-narrow LDDs to our portfolio in the first quarter, bringing our total number of LDDs to 153. Infusion represents one of our larger geographic expansion opportunities looking forward, covering today about one-third of the country on the acute side and half the country in chronic specialty.
Home and community pharmacy is looking to drive organic, profitable growth in assisted living, behavioral, hospice, PACE, skilled nursing, and other markets, supported by investments in automation across our national pharmacy footprint. On the provider side, in our home healthcare businesses, we continue to expect organic growth to be underpinned by market share gains from high-quality services and scaled market development and clinical support teams that we continue to invest in. In 2026, we are integrating the acquired Amedisys and LHC branches and expect approximately $30 million of EBITDA contribution in year one. We are continuously looking to innovate services and associated operational processes to drive outcomes and growth, with numerous payer agreements and partnerships that reflect this.
In palliative and hospice, the strength of our quality results and our patient-centric approach positions us well in a market that remains significantly underutilized, with only half of eligible patients receiving such valuable care today. Rehab continues to deliver consistent growth in home and community settings with excellent clinical outcomes as we continue to expand in the senior setting through Rehab in Motion in assisted living facilities. Home-based primary care and value-based care initiatives, while still in earlier stages, produce meaningful reductions in hospitalization, help coordinate other needed services, and represent significant potential for future growth as we scale. BrightSpring is firmly positioned on the right side of the most important trends in healthcare to address system and patient needs with a differentiated enterprise and a unique set of assets that deliver real solutions to patients, providers, and payers alike. With that context, let me turn to the first quarter.
As a reminder, the company’s financial results in 2026 guidance pertain to continuing operations and do not include results from the divested community living business, nor the impact of any future closed acquisitions. We completed the sale of community living to Sevita on March 30, 2026, which resulted in net cash proceeds before tax of approximately $811 million. The proceeds from this transaction will be used to further strengthen the balance sheet, including both debt paydown and cash availability. Overall, we are pleased with our first quarter financial results with total